Company / SG&A Expense
Biogen SG&A Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$2.4B
FY2025
5-year range
$2.4B / $2.7B
FY2021-FY2025
Trend
+1.2%
vs FY2024
Sector context
#12 of 211
Health Care
What the data says
Among 211 Health Care companies, Biogen is in the bottom 6% for sg&a expense. SG&A Expense has fluctuated over the past 10 years, ranging from $1.9B in FY2017 to $2.7B in FY2021.
Based on SEC 10-K filings.
$2.4B in FY2025 with a 5-year CAGR of -0.6%. Top quartile in the Health Care sector.
Improved from $2.5B to $2.4B over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +0.4%
- 5-Year CAGR
- -0.6%
- 10-Year CAGR
- -
Sector benchmark
Bottom 6% in Health CareTop 94% of 211This company $2.4B Sector average $728.7M
▼
+234.0% above sector average
Key checks
Key Insights
- 5-year CAGR of -0.6%, indicating a declining trend.
- In FY2025, sg&a expense increased 1.2% year-over-year.
- Ranks #12 out of 211 companies in the Health Care sector.
- Peak sg&a expense was recorded in FY2021.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $2.4B | +1.2% |
| FY2024 | $2.4B | -5.7% |
| FY2023 | $2.5B | +6.1% |
| FY2022 | $2.4B | -10.1% |
| FY2021 | $2.7B | +6.8% |
| FY2020 | $2.5B | +5.5% |
| FY2019 | $2.4B | +12.7% |
| FY2018 | $2.1B | +8.9% |
| FY2017 | $1.9B | -0.7% |
| FY2016 | $1.9B | -7.9% |
As of FY2025 · SEC 10-K · Updated Mar 3, 2026